(E)-1-(3,4-dimethoxyphenyl)-3-(3-pyridyl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-1-(3,4-dimethoxyphenyl)-3-(3-pyridyl)prop-2-en-1-one
• 英文别名: DMU716；(e)-3-(3,4-Dimethoxyphenyl)-1-pyridin-3-yl-propenone；(E)-1-(3,4-dimethoxyphenyl)-3-pyridin-3-ylprop-2-en-1-one
• 化学式: C₁₆H₁₅NO₃
• 分子量: 269.3
• InChiKey: QHOMUNQVGOCTOP-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-吡啶甲醛 、 3,4-二甲氧基苯乙酮 在 lithium hydroxide monohydrate 作用下， 以 1,4-二氧六环 为溶剂， 以67%的产率得到(E)-1-(3,4-dimethoxyphenyl)-3-(3-pyridyl)prop-2-en-1-one
  参考文献：
  名称：

  新型吡啶基查耳酮的合成及抗胰酶活性

  摘要：

  合成了一个新颖的吡啶查酮的文库，并进行了罗氏锥虫的筛选。八显示出具有良好的活性与最有效的8具有IC 50 0.29μM的值。用人KB细胞进行的细胞毒性测试表明该化合物具有良好的选择性，选择性指数为47。当该库针对利什曼原虫donovani进行测试时，几乎没有活性。总之，吡啶基查耳酮是开发用于治疗人类非洲锥虫病（HAT）的新型化合物的有希望的先导。

  DOI：

  10.1016/j.ejmech.2017.01.027

文献信息

• Materials and methods involving conditional retention domains
  申请人：ARIAD Gene Therapeutics, Inc.

  公开号：US20030235889A1

  公开（公告）日：2003-12-25

  Materials and methods involving conditional retention domains (CRDs) are disclosed. Also disclosed are fusion proteins containing CRDs and cells expressing such fusion proteins. In addition, the invention provides novel methods for producing target proteins in vivo using fusion proteins containing conditional retention domains and methods for identifying novel CRDs.

  本文公开了涉及条件保持结构域（CRDs）的材料和方法。本发明还公开了含有 CRD 的融合蛋白和表达这种融合蛋白的细胞。此外，本发明还提供了使用含有条件性保留结构域的融合蛋白在体内生产目标蛋白质的新方法，以及鉴定新型 CRD 的方法。
• Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines
  作者：Neill J. Horley、Kenneth J.M. Beresford、Tarun Chawla、Glen J.P. McCann、Ketan C. Ruparelia、Linda Gatchie、Vinay R. Sonawane、Ibidapo S. Williams、Hoon L. Tan、Prashant Joshi、Sonali S. Bharate、Vikas Kumar、Sandip B. Bharate、Bhabatosh Chaudhuri

  DOI：10.1016/j.ejmech.2017.02.016

  日期：2017.3

  The structure of alpha-napthoflavone (ANF), a potent inhibitor of CYP1A1 and CYP1B1, mimics the structure of chalcones. Two potent CYP1B1 inhibitors 7k (DMU2105) and 6j (DMU2139) have been identified from two series of synthetic pyridylchalcones. They inhibit human CYP1B1 enzyme bound to yeast-derived microsomes (Sacchrosomes((TM))) with IC50 values of 10 and 9 nM, respectively, and show a very high level of selectivity towards CYP1B1 with respect to the IC50 values obtained with CYP1A1, CYP1A2, CYP3A4, CYP2D6, CYP2C9 and CYP2C19 Sacchrosomes((TM)). Both compounds also potently inhibit CYP1B1 expressed within 'live' recombinant yeast and human HEK293 kidney cells with IC50 values of 63, 65, and 4, 4 nM, respectively. Furthermore, the synthesized pyridylchalcones possess better solubility and lipophilicity values than ANF. Both compounds overcome cisplatine-resistance in HEK293 and A2780 cells which results from CYP1B1 overexpression. These potent cell-permeable and water-soluble CYP1B1 inhibitors are likely to have useful roles in the treatment of cancer, glaucoma, ischemia and obesity. (C) 2017 Elsevier Masson SAS. All rights reserved.
• MATERIALS AND METHODS INVOLVING CONDITIONAL AGGREGATION DOMAINS
  申请人：ARIAD GENE THERAPEUTICS, INC.

  公开号：EP1123405A1

  公开（公告）日：2001-08-16
• US6566073B1
  申请人：——

  公开号：US6566073B1

  公开（公告）日：2003-05-20
• [EN] MATERIALS AND METHODS INVOLVING CONDITIONAL AGGREGATION DOMAINS<br/>[FR] MATERIAUX ET METHODES IMPLIQUANT DES DOMAINES D'AGREGATION CONDITIONNELLE
  申请人：ARIAD GENE THERAPEUTICS INC

  公开号：WO2000023600A1

  公开（公告）日：2000-04-27

  This document discloses materials and methods involving conditional self-aggregation domains, including fusion proteins containing them, recombinant nucleic acids encoding such fusion proteins, genetically engineered cells containing such recombinant nucleic acids and uses thereof.